Project 190 – What drives the regulation of the zinc transporter ZIP7 in insulin-resistant skeletal muscle? Implications for the treatment of insulin resistance and type 2 diabetes
06 Jan 2020
Dr Stephen Myers – $19,368 Type 2 diabetes (T2D) is one of the fastest growing chronic diseases globally. It affected over 415 million adults in 2015 and is expected to rise to 642 million by 2040. Preceding the development of T2D is insulin resistance (IR), a disorder associated with compromised insulin action on regulating glucose
Project 188 – Exploring high occurrence of childhood asthma in North West Tasmania – an in-depth study
24 Jan 2019
Dr Heinrich Weber – $54,450 Asthma is the most common chronic condition in childhood and the commonest reason for hospitalisation in childhood. Asthma and allergic reaction are generally poorly studied in regional and rural areas.
Project 187 – Prevalence of asthma- chronic obstructive pulmonary disease overlap syndrome (ACOS) in north west Tasmanian population: understanding and translation to early therapy
Dr Sukhwinder Sohal – $55,455 Asthma and COPD are typically characterised as separate diseases with different clinical features, mechanisms and strategies for treatment. However, some patients with respiratory illness appear to have features on both diseases and may exhibit, for example a history of asthma and smoking. Tasmania is the best place to start
Prof. Katie Flanagan- $43,945 Millions of people each year get infected with the influenza virus or flu, many of whom die. Young children are particularly susceptible to severe disease and death from flu. This is likely to be due to differences in the child’s immune system compared to adults who are less susceptible, however
Project 185 – CHESTY – Chest infection prevalence following surgery: an international multicentre observational trial
Ianthe Boden – $40,000 Contracting pneumonia in hospital after surgery is a serious complication and can lead to admission to intensive care, longer in hospital, and at worst, patients can die.